| mAChR | muscarinic acetylcholine receptor |
|---|---|
| AChRs | Acetylcholine Receptors |
| RA | radioactive; ragocyte; ragweed antigen; rapidly adapting [receptors]; reactive arthritis; reciprocal... |
| mAChRs | Muscarinic ACh receptors |
|---|---|
| mAChR | Muscarinic cholinergic receptors |
| M2 | Muscarinic |
| mAChR | Muscarinic acetylcholine receptor |
| mAChR | Muscarinic receptor |
| muscarinic receptors | Membrane-bound proteins whose extracellular domain contains a recognition site for acetylcholine (ACh); combination of Ach with the receptor initiates a physiologic change (slowing of heart rate, increased glandular secretory activity and stimulation of smooth muscle contractions); changes are observed after treatment with the mushroom alkaloid, muscarine. Muscarinic receptors are to be distinguished from nicotinic receptors. (05 Mar 2000) |
|---|
| receptors, muscarinic | One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for muscarine over nicotine. There are several subtypes (usually m1, m2, m3...) that are characterised by their cellular actions, pharmacology, and molecular biology. (12 Dec 1998) |
|---|---|
| muscarinic | 1. Having a muscarine-like action, i.e., producing effects that resemble postganglionic parasympathetic stimulation. 2. An agent that stimulates the postganglionic parasympathetic receptor. See: muscarine, nicotinic. (05 Mar 2000) |
| muscarinic acetylcholine receptor | Distinct from the nicotinic ACh receptor in having no intrinsic ion channel, the receptor is formed from one protein chain with 7 transmembrane regions. The receptors produce their effect via activation of GTP-binding proteins. (18 Nov 1997) |
| muscarinic agonist | Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (12 Dec 1998) |
| muscarinic antagonist | Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine. (05 Mar 2000) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
| muscarinic receptor kinase | <enzyme> Phosphorylates muscarinic acetylcholine receptors and beta-adrenergic receptors Registry number: EC 2.7.- Synonym: muscarinic acetylcholine receptor kinase, machr kinase (26 Jun 1999) |
| adrenergic receptors | Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents. Synonym: adrenoceptor, adrenoreceptors. (05 Mar 2000) |
| alpha-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles. (05 Mar 2000) |
| ANP clearance receptors | Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action. (05 Mar 2000) |
| ANP receptors | Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains. (05 Mar 2000) |
| B-cell antigen receptors | In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors. (05 Mar 2000) |
| beta-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2). (05 Mar 2000) |
| mannose-6-phosphate receptors | Receptors in Golgi apparatus to which newly synthesised proteins that are destined to enter lysosomes bind. (05 Mar 2000) |
| receptors, adrenergic | Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|